ReviewClinical microbiology reviews2012
Predictors of mortality in Staphylococcus aureus Bacteremia.
Review in Clinical microbiology reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 487 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-center Prospective Randomized Open Label Study of Utilizing Interleukin 10 (IL-10) Levels as a Guide for Antibiotic Selection for Methicillin Resistant Staphylococcus Aureus Bacteremia
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase IIa Clinical Study to Evaluate Safety and to Explore Efficacy of N-Rephasin® SAL200, in Patients With Persistent Staphylococcus Aureus Bacteremia
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dosing, Dose-Escalating Phase 1b Study to Evaluate the Safety, PK, PD and Immunogenicity of N-Rephasin® SAL200 After Continuous IV Infusion in Healthy Volunteers
Multicenter, Randomised, Open-label Phase III-IV Study to Evaluate the Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With Methicillin-susceptible Staphylococcus Aureus Bacteraemia: SAFO Trial
Who cites it
487 citing papers in PubMed, 2 syntheses or guidelines pooled it, 917 citations in OpenAlex.
- Antibiotic synergy againstAntimicrobial agents and chemotherapy · 2025Pooled it
- Female Sex and Mortality in Patients with Staphylococcus aureus Bacteremia: A Systematic Review and Meta-analysis.JAMA network open · 2024Pooled it
- Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial.Clinical drug investigation · 2023Trial
- Gut microbiota-driven IL-17A production by hepatic γδ T cells enhances neutrophil defense against systemicVirulence · 2026Article
- Pharmacist-coordinated IDST treatment bundle achievement and impact on mortality in MRSA bacteraemia: a single-centre retrospective cohort study.Infection prevention in practice · 2026Article
- Prevalence and Outcomes of Bacterial Co-detections by Blood Culture Among Children and Adults Hospitalized With Laboratory-confirmed Influenza, Influenza Hospitalization Surveillance Network, 2022-2024.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Intranasal immunization in mice with spore-associated serine-aspartate repeat-containing protein D from Staphylococcus aureus secreted in Bacillus subtilis.Biotechnology letters · 2026Article
- Factors associated with methicillin resistance in Staphylococcus aureus: a case-case-control analysis of AMR surveillance data.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Impact of a standardized management protocol and antimicrobial stewardship intervention on mortality and quality of care in Staphylococcus aureus bacteremia: a before-after study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- An Achilles' heel for methicillin-resistantAntimicrobial agents and chemotherapy · 2026Review
- Characterization of beddomeilactone amide as bacterial DNA gyrase inhibitor: in vitro evaluation and computational insights.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Clinical Characteristics, Empirical Antibiotic Appropriateness, and Outcomes of Gram-Positive Versus Gram-Negative Bacteremia in Emergency Department Patients with Sepsis.Medicina (Kaunas, Lithuania) · 2026Article
- Methicillin-resistant Staphylococcus aureus bloodstream infections in the Northern Territory of Australia 2017-2022.Internal medicine journal · 2026Observational
- Article
- In Silico Prioritisation of Similarity-Selected Small Molecules Targeting the IsdB NEAT Domain ofInternational journal of molecular sciences · 2026Article
- ThebioRxiv : the preprint server for biology · 2026Article
- Staphylococcus aureus bacteremia: clinical outcomes and predictors of 28-day mortality in a tertiary-care cohort.BMC infectious diseases · 2026Article
- Surgical treatment of acute empyema caused by methicillin-resistantJournal of surgical case reports · 2026Article
- Article
- Impact of Methicillin Resistance on Outcomes ofOpen forum infectious diseases · 2026Article
427 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus bacteremia (SAB) is an important infection with an incidence rate ranging from 20 to 50 cases/100,000 population per year. Between 10% and 30% of these patients will die from SAB. Comparatively, this accounts for a greater number of deaths than for AIDS, tuberculosis, and viral hepatitis combined. Multiple factors influence outcomes for SAB patients. The most consistent predictor of mortality is age, with older patients being twice as likely to die. Except for the presence of comorbidities, the impacts of other host factors, including gender, ethnicity, socioeconomic status, and immune status, are unclear. Pathogen-host interactions, especially the presence of shock and the source of SAB, are strong predictors of outcomes. Although antibiotic resistance may be associated with increased mortality, questions remain as to whether this reflects pathogen-specific factors or poorer responses to antibiotic therapy, namely, vancomycin. Optimal management relies on starting appropriate antibiotics in a timely fashion, resulting in improved outcomes for certain patient subgroups. The roles of surgery and infectious disease consultations require further study. Although the rate of mortality from SAB is declining, it remains high. Future international collaborative studies are required to tease out the relative contributions of various factors to mortality, which would enable the optimization of SAB management and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.